Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens.
OBJECTIVE
The capacity to properly address the worldwide incidence of infectious diseases lies in the ability to detect, prevent and effectively treat these infections. Therefore, identifying and analysing inhibitory agents are worthwhile endeavours in an era when few new classes of effective antimicrobials have been developed. The use of geological nanomaterials to heal skin infections has been evident since the earliest recorded history, and specific clay minerals may prove valuable in the treatment of bacterial diseases, including infections for which there are no effective antibiotics, such as Buruli ulcer and multidrug-resistant infections.


METHODS
We have subjected two iron-rich clay minerals, which have previously been used to treat Buruli ulcer patients, to broth culture testing of antibiotic-susceptible and antibiotic-resistant pathogenic bacteria to assess the feasibility of using clay minerals as therapeutic agents.


RESULTS
One specific mineral, CsAg02, demonstrated bactericidal activity against pathogenic Escherichia coli, extended-spectrum beta-lactamase (ESBL) E. coli, Salmonella enterica serovar Typhimurium, Pseudomonas aeruginosa and Mycobacterium marinum, and a combined bacteriostatic/bactericidal effect against Staphylococcus aureus, penicillin-resistant S. aureus, methicillin-resistant S. aureus (MRSA) and Mycobacterium smegmatis, whereas another mineral with similar structure and bulk crystal chemistry, CsAr02, had no effect on or enhanced bacterial growth. The <0.2 microm fraction of CsAg02 and CsAg02 heated to 200 or 550 degrees C retained bactericidal activity, whereas cation-exchanged CsAg02 and CsAg02 heated to 900 degrees C no longer killed E. coli.


CONCLUSIONS
Our results indicate that specific mineral products have intrinsic, heat-stable antibacterial properties, which could provide an inexpensive treatment against numerous human bacterial infections.
Haydel
Shelley E
SE
Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ, USA. shelley.haydel@asu.edu
Remenih
Christine M
CM
Williams
Lynda B
LB
D000538:Aluminum Silicates / Q000302:isolation & purification / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000302:isolation & purification / Q000494:pharmacology*; D000077215:Clay; D024881:Drug Resistance, Bacterial / Q000187:drug effects / Q000502:physiology; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects* / Q000502:physiology; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000502:physiology; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000502:physiology; D008826:Microbial Sensitivity Tests / Q000379:methods
D000538:Aluminum Silicates; D000900:Anti-Bacterial Agents; D000077215:Clay